|Day Low/High||10.01 / 10.29|
|52 Wk Low/High||6.36 / 16.81|
These heavily shorted pharmaceutical stocks could surge higher on any positive catalyst.
Theravance says FDA wants more data before ruling on Vitabix for hospital-acquired pneumonia
FDA doesn't raise new safety issues for Auxilium's hand treatment
Jim Bianco unloads 30% of holdings days after investor meeting.
A quick and dirty guide to important biotech events for the busy month of September.
A quick and dirty guide to upcoming FDA approval dates for biotech drugs.
Theravance's 1st-quarter loss narrows on cost cuts, higher revenue from partnerships
The FDA has deemed two trials for oritavancin insufficient for approval.
Shares dive 28% on signs of further regulatory delays for its drug telavancin.
Shares soar 18.5% after Oracle successfully bids for the company.
$10.7 billion wasn't enough to satisfy INTC analysts and the stock plunged.
The committee soon will meet to discuss the new-drug application for skin-infection drug Telavancin.
Adolor is plunging after halting a clinical trial for a constipation drug.
Cell Genesys jumps after its prostate cancer treatment does well in a trial.
Theravance climbs on positive results for a proposed asthma treatment.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.